Aprea Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
All right. Good morning, everyone, and welcome to OpCo's 33rd Annual Healthcare Conference. My name is Matt Hagood. I'm on the emerging biotech team here at OpCo. So our next presenting company is Aprea Therapeutics. I'm pleased to be joined by CEO, Oren Gilad. Oren, welcome.
Before we start, I'll just add that if there are any questions from the audience, feel free to type those in the box below your screen. And with that, Oren, the floor is yours.
Thank you, Matt, and thank you for the Oppenheimer team for the invitation to present in the conference. This is our disclosure. Aprea is oncology company focusing on synthetic lethality and the DNA damage response pathway.
We have chosen to target a clinical pathway with multiple targets. So we're looking at the ATR, which our drug is in clinical stage in human, and WEE1, which is in IND-enabling studies. We also have undisclosed programs as well as innovative platform that we're going to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
